We’re excited to announce a strategic collaboration with NuvOx Therapeutics to support their Phase 2b #glioblastoma trial, funded by a grant from the National Cancer Institute (NCI). Under the award, FYR will apply its EV-Omics™ (EVO) platform and SPARCs™ enrichment technology to longitudinal blood samples collected in NuvOx’s RESTORE trial of NanO₂™, a radiosensitizer designed to reverse tumor hypoxia. The collaboration will explore extracellular-vesicle biomarkers that reflect hypoxia biology, correlate with treatment exposure, and help clinicians differentiate pseudoprogression from true progression—a persistent challenge in glioblastoma management. We’re proud to contribute to this important effort alongside NuvOx and look forward to advancing meaningful outcomes for patients impacted by glioblastoma. Read full press release here: https://lnkd.in/gW2VNnye 📌 Interested in learning more about our EV‑Omics technology or exploring how liquid biopsies can enhance your clinical trial program? Contact us at bd@fyr.bio.
FYR Bio
Biotechnology Research
Missoula, MT 1,573 followers
The catalyst to innovate diagnostics and transform healthcare.
About us
FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable the deep assessment of proteins and nucleic acids from a simple blood draw. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring. For more, visit fyr.bio.
- Website
-
https://fyr.bio/
External link for FYR Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Missoula, MT
- Type
- Privately Held
Locations
-
Primary
Get directions
1121 E Broadway St
Missoula, MT 59802, US
Employees at FYR Bio
-
Brian Conway MBA
-
Philippe Nore
Executive operating at the intersection of Life Sciences and Technology | Board Member | Entrepreneur
-
Kirk Tanner
Dedicated Drug Hunter striving to advance new treatments to brain cancer, ovarian cancer, hepatocellular cancer, pancreatic cancer and pediatric…
-
Sarjubhai Patel
Associate Research Professor at University of Montana President & Co-Founder FYR Diagnostics
Updates
-
FYR Bio reposted this
This week, we’re headed to the 2025 Society for Neuro-Oncology Annual Meeting! The FYR team is excited to connect with the #NeuroOncology community and share our latest work exploring the proteomic fingerprints of malignant #glioma. 📌 Poster: Sex-associated Biomarker Signatures in Malignant Glioma: Insights from a Proteomics Study 🗓 Nov. 22, 11:45 a.m. - 1:05 p.m. HST 📍 Kamehameha Exhibit Hall II & III, Hawaii Convention Center If you’ll be at #SNO2025, stop by to learn how protein-based insights may help reveal new ways to understand and treat this challenging disease. Learn more: https://lnkd.in/dfQ5zdzp #PrecisionMedicine #Biomarkers #BrainTumorResearch #Glioblastoma
-
-
This week, we’re headed to the 2025 Society for Neuro-Oncology Annual Meeting! The FYR team is excited to connect with the #NeuroOncology community and share our latest work exploring the proteomic fingerprints of malignant #glioma. 📌 Poster: Sex-associated Biomarker Signatures in Malignant Glioma: Insights from a Proteomics Study 🗓 Nov. 22, 11:45 a.m. - 1:05 p.m. HST 📍 Kamehameha Exhibit Hall II & III, Hawaii Convention Center If you’ll be at #SNO2025, stop by to learn how protein-based insights may help reveal new ways to understand and treat this challenging disease. Learn more: https://lnkd.in/dfQ5zdzp #PrecisionMedicine #Biomarkers #BrainTumorResearch #Glioblastoma
-
-
We're just a week away from the 2025 Society for Neuro-Oncology Annual Meeting in Honolulu! This year marks 30 years of advancing science, innovation, and collaboration in neuro-oncology, and we’re proud to be part of it. Our team is looking forward to engaging with leaders in brain tumor research and care and sharing how FYR’s EV-Omics Platform is helping drive more precise protein and nucleic acid insights in neuro-oncology. Hope to see you at #SNO2025!
-
-
This week, the FYR team is onsite at Oxford Global’s Biomarkers & Precision Medicine USA 2025 in San Francisco! We're proud to sponsor this dynamic event, bringing together leaders at the forefront of innovation in precision medicine. We're also excited to share how our multiomic-based biomarker platforms are driving better clinical development in precision medicine. 📍 Stop by booth #9 to learn more and connect with our team. #Biomarkers #PrecisionMedicine #Biotech #EarlyDetection #BPM2025
-
-
Its #InternationalBrainTumorWeek and we’re joining the global community to raise awareness about brain tumors—one of the most challenging and complex forms of cancer. Early detection and innovative diagnostics are crucial to improving patient outcomes and quality of life. Our team is committed to advancing protein-based blood tests that can reveal the molecular signatures of brain tumors earlier and more precisely than ever before. By unlocking these insights, we empower clinicians with better tools to tailor treatments and give patients hope. Together, we can accelerate progress in brain tumor detection and care. #Glioblastoma #IBTAWeek #BrainCancer #EarlyDetection #PrecisionMedicine #Biomarkers
-
-
The FYR team is gearing up for next week’s Oxford Global’s Biomarkers & Precision Medicine USA 2025! As proud sponsors of this leading event, the FYR team is looking forward to connecting with researchers, clinicians and industry innovators who are shaping the future of #PrecisionMedicine. Visit us at booth #9 to meet the team and explore how our multiomic-based #Biomarker platforms are enabling smarter, faster #ClinicalDevelopment. See you in San Francisco! #InnovationInMedicine #Biotech #EarlyDetection #BPM2025
-
-
#ICYMI FYR has integrated CIQ Fuzzball to help scale our AI-Enabled EVO platform, amplifying our ability to: Interpret complex biology at scale Move from exploratory models to production-ready analytics in record time Deliver reproducible results, high-quality data With this collaboration, we’re driving #Biomarker discovery, accelerating clinical trial readiness, and pushing the boundaries of #PrecisionMedicine. Learn more: https://lnkd.in/gVJNnVGJ #ExtracellularVesicles #AIinBiotech
Powering precision medicine at scale. We've partnered with FYR Bio to integrate Fuzzball into their AI-enabled EV-Omics platform, enabling 100x throughput and reproducible, FDA-ready pipelines in hours instead of weeks. "CIQ's Fuzzball gives us the ability to implement and scale these pipelines for 100x the throughput in a fraction of the time." — Claire Seibold, Director of Software and Data Analytics, FYR “The partnership between FYR and CIQ demonstrates the impact of strategic collaboration,” said Mark Adams, Ph.D., partner at Two Bear Capital. “By integrating CIQ’s Fuzzball into FYR’s EV-Omics platform, these two companies can deliver faster, high-quality insights that accelerate biomarker discovery and advance precision medicine, ultimately generating meaningful outcomes for patients.” Read the announcement: https://lnkd.in/gbUdRqyS #PrecisionMedicine #AIinHealthcare #Biotech #Pharma #HighPerformanceComputing #LifeSciences
-
-
FYR has integrated CIQ's Fuzzball to help scale EVO, our AI-enabled EV-Omics platform. Fuzzball enables us to process complex data at production scale and create reproducible, high-quality analytical pipelines in hours, not days. By moving AI models from laptop prototypes to production-ready environments—and supporting the rigor needed for GLP/GxP/FDA work—this integration underscores our commitment to helping pharma and research partners access scalable, reproducible insights faster. Read the full announcement: https://lnkd.in/eKi2424X #PrecisionMedicine #ExtracellularVesicles #Biomarkers #AIinBiotech
-
We’re excited to share a new $8M financing to accelerate our mission. Joining our long-standing investor, Two Bear Capital, are The Sontag Innovation Fund (venture arm of The Sontag Foundation) and the Yuvaan Tiwari Foundation. This funding enables us to: • Accelerate FYR’s continued expansion in oncology • Add emphasis in neuroscience—including neuro-oncology and neurodegeneration • Deliver high-quality, blood-based insights that inform clinical decisions Our EVO platform turns complex biology into reliable, actionable data from a simple blood draw—supporting better biomarkers, better trials, and better outcomes. We’re grateful for the continued support from Two Bear Capital and excited to welcome The Sontag Innovation Fund and the Yuvaan Tiwari Foundation to the FYR community. Learn more: fyr.bio #Biomarkers #Oncology #Neuroscience #ExtracellularVesicles #PrecisionMedicine